Pertuzumab biosimilar (Hengrui Pharma)

帕妥珠单抗生物类似药（恒瑞）

Report date: 2025/06/26 20:00:07

Base Information

Drug NamePertuzumab biosimilar (Hengrui Pharma)
Drug Alias NameSHR-1309
ClassificationBiologics > Protein drugs > Immunoglobulin > AntibodyBiologics > Biosimilar
Mechanisms of ActionIonising radiation emittersReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancer
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Hengrui Pharmaceutical Co LtdJiangsu Hengrui Medicine Co Ltd
Active IndicationsN/A
Inactive IndicationsMetastatic breast cancer

Other Information

ATC CodeN/A
Related LinksN/A